Wall Street Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Wall Street Associates’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-15,142	Closed	-$530K	–	281
2015 Q4	$530K	Sell	15,142 -5,987	-28%	-$386K	0.15%	201
2015 Q3	$1.94M	Sell	21,129 -6,614	-24%	-$572K	0.37%	87
2015 Q2	$2.44M	Sell	27,743 -5,801	-17%	-$497K	0.23%	114
2015 Q1	$2.49M	Sell	33,544 -1,502	-4%	-$106K	0.24%	129
2014 Q4	$1.96M	Buy	35,046 +5,611	+19%	+$295K	0.19%	150
2014 Q3	$1.33M	Sell	29,435 -4,840	-14%	-$202K	0.14%	183
2014 Q2	$1.42M	Sell	34,275 -4,080	-11%	-$210K	0.12%	193
2014 Q1	$2.66M	Sell	38,355 -86,017	-69%	-$6.32M	0.22%	138
2013 Q4	$7.5M	Buy	124,372 +44	+0%	+$2.39K	0.61%	52
2013 Q3	$7.56M	Sell	124,328 -186,012	-60%	-$13.2M	0.71%	38
2013 Q2	$20.8M	Buy	+310,340	New	+$14M	2.12%	4

Other funds holding CLVS

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wall Street Associates's CLVS Position: Q1 2016 in Review

Wall Street Associates sold out of Clovis Oncology, Inc. (CLVS) in Q1 2016, closing a stake of 15,142 shares — an estimated $530K sold.

Wall Street Associates first reported a position in CLVS in Q2 2013 and held it in 11 quarters. The position peaked at $20.8M in Q2 2013. 135 funds tracked by Wall St. Rank hold CLVS as of Q1 2016.

Wall Street Associates reported no remaining Clovis Oncology, Inc. position as of Q1 2016 after selling out during the quarter.
Wall Street Associates sold 15,142 Clovis Oncology, Inc. shares in Q1 2016, an estimated $530K.
Wall Street Associates first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 11 quarters.
Wall Street Associates's Clovis Oncology, Inc. position peaked at $20.8M in Q2 2013.
135 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2016.

Based on Wall Street Associates's 13F filing for Q1 2016, filed 13 May 2016.